Publication

Article

Oncology & Biotech News

December 2009
Volume0

Do Insurers Spend Too Much on Administration and Too Little on Care?

Author(s):

Onclive Team

Articles in this issue
Amgen Honored for Best Pipeline & Best New Drug
Do Insurers Spend Too Much on Administration and Too Little on Care?
The Effect of New Treatments on Cancer-related Bone Loss
Exercise Maintains Function, Improves QoL for Patients With Lymphoma
Continuing Education Opportunities on the Web
Ramucirumab (IMC-1121B): A Novel Fully Human Monoclonal Antibody that Targets VEGFR-2
News Briefs & FDA Updates
News & Opinion
Decline in Cancer Deaths No Reason to Get Complacent
Related Videos
Sam Brondfield, MD, MA
Related Content
Recap of every episode of OncLive On Air® that aired in October 2024
November 1st 2024

Revisit Every OncLive On Air Episode From October 2024

Sorting Through Sexism, Guilt, and Motherhood in Medicine
January 27th 2022

Sorting Through Sexism, Guilt, and Motherhood in Medicine

Kimberly Futch, MBA
September 23rd 2024

AI Is Poised to Influence Several Areas of Cancer Care With Some Fine-Tuning

Gilbert on Gaining New Ground at Vanderbilt
January 3rd 2022

Gilbert on Gaining New Ground at Vanderbilt

Jeff Patton, MD
September 4th 2024

A Decrease in Innovation Is a Large Concern With New IRA Policies in Oncology

Debra Patt, MD, PhD, MBA, FASCO
September 3rd 2024

Vice President of COA Unpacks Effects of the Medicare Drug Price Negotiation Program in the Community